Page 353 - Read Online

Sharma et al. Neuroimmunol Neuroinflammation 2018;5:43 I http://dx.doi.org/10.20517/2347-8659.2018.51 Page 11 of 12

Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science
2011;331:1565-70.
2. Sampson JH, Maus MV, June CH. Immunotherapy for brain tumors. J Clin Oncol 2017;35:2450-6.
3. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, et al. Structural and functional features of central nervous system lymphatic
vessels. Nature 2015;523:337-41.
4. Walsh JT, Watson N, Kipnis J. T cells in the central nervous system: messengers of destruction or purveyors of protection? Immunology
2014;141:340-4.
5. Mohme M, Neidert MC, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma.
Cancer Treat Rev 2014;40:248-58.
6. Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 2010;21:17-29.
7. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, et al. Human leukocyte antigen and antigen processing machinery component
defects in astrocytic tumors. Clin Cancer Res 2005;11:8304-11.
8. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-8.
9. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015;7:280ps7.
10. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res
2003;9:4296-303.
11. Fousek K, Ahmed N. The evolution of T-cell therapies for solid malignancies. Clin Cancer Res 2015;21:3384-92.
12. Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, et al. A Tet-On inducible system for controlling CD19-chimeric antigen
receptor expression upon drug administration. Cancer Immunol Res 2016;4:658-68.
13. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64-73.
14. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using
chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012;32:1059-70.
15. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. Eradication of B-lineage cells and regression of
lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.
16. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J
Med 2011;365:725-33.
17. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with
chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
18. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N
Engl J Med 2013;368:1509-18.
19. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, et al. T cells genetically modified to express an anti-B-cell maturation antigen
chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018;36:2267-80.
20. Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program
2014;2014:559-64.
21. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019
in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577.
22. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic
leukemia. N Engl J Med 2018;378:439-48.
23. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, et al. Chimeric antigen receptor T-cell therapy - assessment and
management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
24. Abramson JS, McGree B, Noyes S, Plummer S, Wong C, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl
J Med 2017;377:783-4.
25. Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res 2018;6:4.
26. Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts):
combination or built-in CAR-T. Int J Mol Sci 2018;19:E340.
27. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor
CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res 2015;21:4062-72.
28. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N
Engl J Med 2016;375:2561-9.
29. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, et al. A single dose of peripherally infused EGFRvIII-directed CAR
T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9:eaaa0984.
30. Nelson R. Juno permanently halts CAR T-cell study. In: Medscape Medical News. Online: Medscape; 2017.
31. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321-30.
32. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, et al. Current concepts in the diagnosis and management of cytokine release
syndrome. Blood 2014;124:188-95.